A Phase II, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of GDC-9545 Compared With Physician's Choice of Endocrine Monotherapy in Patients With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
A Phase II, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of GDC-9545 Compared With Physician's Choice of Endocrine Monotherapy in Patients With Previously Treated Estrogen Receptor-Positive, HER2-Negative Locally Advanced or Metastatic Breast Cancer
This Phase II, randomized, open-label, multicenter study will evaluate the efficacy and safety of giredestrant compared with physician's choice of endocrine monotherapy in participants with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer who have received one or two prior lines of systemic therapy in the locally advanced or metastatic setting.
Inclusion Criteria:
Exclusion Criteria:
São Paulo, São Paulo 01317-001, Brazil
Krasnoyarsk, Krasnodarskiy Kray 660133, Russia
Pesochny, Leningrad 197758, Russia
Moskva, Moscow Oblast 115478, Russia
Nizhny Novgorod, Niznij Novgorod 603081, Russia
Saint Petersburg, Sankt-Peterburg 197022, Russia
Kazan', Tatarstan Republic 420029, Russia
Dongnam-gu, Cheonan-si, 31151, South Korea
Taoyuan Hsien, 333, Taiwan
Chang Mai, 50200, Thailand